Drug Profile
Research programme: coronavirus vaccines - Novavax
Alternative Names: COVID-2019 combination bivalent vaccine; MERS vaccine - Novavax; Middle East Respiratory Syndrome Coronavirus (MERS-CoV) vaccine - NovavaxLatest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Novavax
- Class COVID-19 vaccines; Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
- No development reported Middle East respiratory syndrome coronavirus
- Discontinued Severe acute respiratory syndrome
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Middle-East-respiratory-syndrome-coronavirus(Prevention) in USA
- 01 Mar 2021 Preclinical development in Middle-East-respiratory-syndrome-coronavirus (Prevention) is ongoing in USA (Novavax FORM 10-K, March 2021)
- 01 Mar 2021 Preclinical trials in COVID-2019 infections (Prevention) in USA (Novavax FORM 10-K, March 2021)